The Use of Somatic Hypermutation for the Affinity Maturation of Therapeutic Antibodies
Authors:
- 9 September 2018
- book chapter
- Published by Springer Nature
- Vol. 1827, 479-489
Abstract
The engineering of antibodies and antibody fragments for affinity maturation, stability, and other biophysical characteristics is a common aspect of therapeutic development. Maturation of antibodies in B cells during the adaptive immune response is the result of a process called somatic hypermutation (SHM), in which the activation-induced cytidine deaminase (AID) acts to introduce mutations into immunoglobulin (Ig) genes. Iterative selection and clonal expansion of B cells containing affinity-enhancing mutations drive an increase in the overall affinity of antibodies. Here we describe the use of SHM coupled with mammalian cell surface display for the maturation of antibodies in vitro and the complementarity of these methods with the mining of immune lineages using next-generation sequencing (NGS).Keywords
This publication has 24 references indexed in Scilit:
- General strategy for the generation of human antibody variable domains with increased aggregation resistanceProceedings of the National Academy of Sciences, 2012
- Activation-induced Cytidine Deaminase in B Cell Immunity and CancersImmune Network, 2012
- Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodiesProceedings of the National Academy of Sciences, 2011
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- The Biochemistry of Somatic HypermutationAnnual Review of Immunology, 2008
- Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coliNature Biotechnology, 2007
- Generation and iterative affinity maturation of antibodies in vitro using hypermutating B-cell linesNature Biotechnology, 2002
- AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversificationNature, 2002
- Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues 1 1Edited by J. A. WellsJournal of Molecular Biology, 1999
- Humanization of a mouse monoclonal antibody by CDR–grafting: the importance of framework residues on loop conformationProtein Engineering, Design and Selection, 1991